dendritic cell vaccine therapy + fludeoxyglucose F 18 + laboratory biomarker analysis + NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL + positron emission tomography + FLUDARABINE PHOSPHATE + Cyclophosphamide + ALDESLEUKIN for neoplasms
A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set
Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.
Put together by software, not yet checked by a person